Erasca Inc. (NASDAQ:ERAS) reported updated preliminary Phase 1 data for its investigational pan-RAS molecular glue ERAS-0015, citing encouraging early activity in RAS-mutant solid tumors while outlining plans to advance the candidate into potentially registration-enabling studies.
The clinical-stage oncology company also priced an upsized public offering expected to generate approximately $550 million to support its pipeline and broader operations.
Read Next
Biotech
Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?
